The upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023 is just around the corner, and leading pharmaceutical giants like BMS, Genmab, AstraZeneca, Regeneron, BeiGene, ADC Therapeutics, Eli Lilly and Company, Janssen, and others are gearing up for this conference. This conference will provide a platform to highlight the expanding array of treatment options available for blood cancers and disorders. The focus lies on identifying key abstracts that are anticipated to leave a lasting impression, sparking significant interest throughout the event.

Highlighting the Featured Abstracts at ASH 2023: A Must-See List!

CompanyDrugTrial ID/ AcronymPhaseAbstract No.Abstract Title
Diffuse large B cell lymphoma (DLBCL)
C:\Users\HP00\Desktop\Comapny's Logo\download (36).pngOdronextamabNCT03888105 (ELM-2)II436Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
C:\Users\HP00\Desktop\Comapny's Logo\JOBS-LOGO-en-us-1600113636581.pngLisocabtagene maraleucelNCT03483103(PILOT)II105Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\3EB82D25.tmpEpcoritamab + lenalidomideNCT05283720 (EPCORE NHL-5)II438Subcutaneous Epcoritamab Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma from EPCORE NHL-5
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\6D8E9DBF.tmpBgb-16673NCT05006716I/II4401First Results from a Phase 1, First-in-Human Study of the Bruton’s Tyrosine Kinase Degrader Bgb-16673 in Patients with Relapsed or Refractory B-Cell Malignancies (BGB-16673-101)
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\3EB82D25.tmpEpcoritamab + GemOxNCT04663347 (EPCORE NHL-2)Ib/II3092Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from EPCORE NHL-2
Epcoritamab + R-mini-CHOP4457Subcutaneous Epcoritamab + R-mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose Anthracycline: Results from the EPCORE NHL-2 Phase 1/2 Trial. 
Follicular Lymphoma (FL)
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\3EB82D25.tmpEpcoritamab + rituximab + lenalidomideNCT05409066 (EPCORE FL-1)III3053EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab With Rituximab and Lenalidomide (R2) vs R2 Alone in Patients With Relapsed or Refractory Follicular Lymphoma.
C:\Users\HP00\Desktop\Comapny's Logo\download (32).pngLoncastuximab tesirine + rituximabNCT04998669II984Limited Duration Loncastuximab Tesirine with Rituximab Induces High Complete Metabolic Response Rate in High-Risk Relapsed/Refractory Follicular Lymphoma – A Phase 2 Study
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\3EB82D25.tmpEpcoritamabNCT03625037 (EPCORE NHL-1)I/II1655Epcoritamab SC Monotherapy Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: Results from the EPCORE NHL-1 Dose Expansion Cohort.
C:\Users\HP00\Desktop\Comapny's Logo\download (1).pngPirtobrutinib NCT03740529 (BRUIN)I/II3026Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study
Multiple Myeloma (MM)
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\CB007F7B.tmpDaratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone NCT03710603 (PERSEUS)IIILBA1Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\CB007F7B.tmpCiltacabtagene autoleucelNCT04181827 (CARTITUDE-4)III1063Patient-reported outcomes in the Phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel versus standard of care in patients with lenalidomide-refractory multiple myeloma after 1-3 lines of therapy
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\CB007F7B.tmpDaratumumab, bortezomib, melphalan, and prednisoneNCT03217812 (OCTANS)III3388Daratumumab, bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (V-MP) alone in transplant-ineligible Asian patients with NDMM: final analysis of the Phase 3 OCTANS study
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\CB007F7B.tmpDaratumumabNCT02316106(CENTAURUS)II210Efficacy and safety of daratumumab monotherapy in patients with intermediate-risk or high-risk SMM: final analysis of the Phase 2 CENTAURUS study
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\6D8E9DBF.tmpSonrotoclax (BGB-11417) + dexamethasoneNCT04973605Ib/II1011Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\3EB82D25.tmpGEN3014NCT04824794I/II4757GEN3014 (HexaBody-CD38) in Anti-CD38 mAb–Naive Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a Dose-Expansion Cohort of a Phase 1/2 Trial. 
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\CB007F7B.tmpTalquetamab + pomalidomideNCT05050097 (MonumenTAL-2)Ib1014Talquetamab + pomalidomide in patients with RRMM: safety and preliminary efficacy results from the Phase 1b MonumenTAL-2 study
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\CB007F7B.tmpJNJ-79635322NCT05652335I456Characterization of JNJ-79635322, a novel BCMA x GPRC5D x CD3 T-cell redirecting trispecific antibody, for the treatment of multiple myeloma
C:\Users\HP00\Desktop\Comapny's Logo\JOBS-LOGO-en-us-1600113636581.pngBMS-986393NCT04674813I219BMS-986393 (CC-95266), a G protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\6D8E9DBF.tmpSonrotoclax + zanubrutinibNCT04277637Ia/Ib327Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Data from an Ongoing Phase 1/2 Study
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\2125C241.tmpLisaftoclaxNCT03913949, NCT04494503Ib/II1900Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pool Analysis of Two Clinical Trials
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\C90DFEF7.tmpSelinexorNCT04562389  (XPORT-MF-034)III3209A Global, Phase 3, Randomized,
Double-Blind Study to Evaluate Safety  and Efficacy of Selinexor, an XPO-1  Inhibitor in Combination with  ruxolitinib in JAK Inhibitor-Naïve  Myelofibrosis (XPORT-MF-034)
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\B8FF7B1D.tmpPelabresib + ruxolitinibNCT04603495III628Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
Mantle cell lymphoma (MCL)
C:\Users\HP00\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\7A581833.tmpIbrutinib + venetoclaxNCT03112174 (SYMPATICO)IIILBA2Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
AstraZeneca - Metastatic Breast Cancer AllianceAcalabrutinib + venetoclax and rituximabNCT05951959 (TrAVeRse)II3054TrAVeRse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment- naïve Mantle Cell Lymphoma
C:\Users\HP00\Desktop\Comapny's Logo\download (1).pngPirtobrutinibNCT03740529(BRUIN)I/II981Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study